

MATERIALS LICENSE

Amendment No. 16

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

301840

Licensee

1. Bethesda Hospital
2. 2951 Maple Avenue
Zanesville, OH 43701

In accordance with the letter dated
August 30, 19963. License Number 34-16710-01 is amended in
its entirety as follows:

4. Expiration Date January 31, 2005

5. Docket or
Reference No. 030-115226. Byproduct, Source, and/or
Special Nuclear Material7. Chemical and/or Physical
Form8. Maximum Amount that Licensee
May Possess at Any One Time
Under This LicenseA. Any byproduct
material identified
in 10 CFR 35.100A. Any
radiopharmaceutical
identified in 10 CFR
35.100

A. As needed

B. Any byproduct
material identified
in 10 CFR 35.200B. Any
radiopharmaceutical
identified in 10 CFR
35.200

B. As needed

C. Any byproduct
material identified
in 10 CFR 35.300C. Any
radiopharmaceutical
identified in 10 CFR
35.300C. As needed (not to
exceed 10 curies of
I-131)D. Any byproduct
material identified
in 10 CFR 35.400D. Any brachytherapy
sources identified
in 10 CFR 35.400

D. As needed

E. Any byproduct
material identified
in 10 CFR 35.500E. Sealed sources
identified in 10 CFR
35.500

E. As needed

F. Any byproduct
material identified
in 10 CFR 31.11

F. Prepackaged Kits

F. As needed

9. Authorized Use:

- A. Medical use described in 10 CFR 35.100.
- B. Medical use described in 10 CFR 35.200.

9610220213 960924
PDR ADOCK 03011522
C PDR

COPY

9/
ML
230
SD

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number

34-16710-01

Docket or Reference Number

030-11522

Amendment No. 16

- C. Medical use described in 10 CFR 35.300.
- D. Medical use described in 10 CFR 35.400.
- E. Medical use described in 10 CFR 35.500 in devices which have been evaluated and approved for licensing purposes by the U.S. Nuclear Regulatory Commission or an Agreement State.
- F. In vitro studies.

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at 2951 Maple Avenue, Zanesville, Ohio.
11. A. Radiation Safety Officer: M. A. Graber, M.D.
B. Assistant Radiation Safety Officer: D. R. Boyse, M.D.
12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized UsersMaterial and Use

- | | |
|----------------------------|---|
| A. D. R. Boyse, M.D. | 10 CFR 35.100, 35.200, 35.300, 35.400, 35.500 and 31.11. |
| B. J. S. Safko, M.D. | 10 CFR 35.100, 35.200, 35.300, 35.400, 35.500 and 31.11. |
| C. J. W. Steinberger, M.D. | 10 CFR 35.100, 35.200, and phosphorus-32 for treatment of polycythemia vera, leukemia, and bone metastases. |
| D. J. Greenspan, M.D. | 10 CFR 35.100, 35.200 and 35.300. |
| E. M. A. Graber, M.D. | 10 CFR 35.100, 35.200 and 35.300. |
| F. R. L. Mellon, M.D. | 10 CFR 35.100 and 35.200. |
| G. Z. S. Kaka, M.D. | 10 CFR 35.300, 35.400 and 35.500. |
| H. B. A. Merwin, M.D. | Strontium-89, as included in 10 CFR 35.300, and 10 CFR 35.400. |

COPY

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

34-16710-01

Docket or Reference Number

030-11522

Amendment No. 16

Authorized Users

Material and Use

I. C. Muchnok, M.D.

10 CFR 35.100 and 35.200.

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated July 7, 1994.



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date

9/24/96

By

Michael F. Weber

Nuclear Materials Licensing Branch, Region III

COPY

BETWEEN:

License Fee Management Branch, ARM
and
Regional Licensing Sections

(FOR LFMS USE)
INFORMATION FROM LTS

Program Code: 02120
Status Code: 0
Fee Category: 7C
Exp. Date: 20050131
Fee Comments:
Decom Fin Assur Req: N

52
22

LICENSE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED

Applicant/Licensee: BETHESDA HOSPITAL
Received Date: 960917
Docket No: 3011522
Control No.: 301840
License No.: 34-16710-01
Action Type: Amendment

2. FEE ATTACHED

Amount: *
Check No.: *

* addl info
301564-52

3. COMMENTS

Signed J. Hensley
Date 9-17-96

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered)

1. Fee Category and Amount: Continuation 301564

2. Correct Fee Paid. Application may be processed for:

Amendment ✓
Renewal
License

3. OTHER

Signed SC
Date 9/24/96

1996 SEP 23 AM 11:22

SEP 30 1996

RECEIVED BY LFDCB

Date Sept. 23, 1996

Log SEP 9 III

By SC

Date Completed 9/24/96

BETHESDA

HOSPITAL

*We pledge
to put the patient first;
to succeed through teamwork;
to strive for continuous improvement.*

2951 North Maple Avenue
Zanesville, Ohio 43701
(614) 454-4000

August 30, 1996

Michael F. Weber
Nuclear Materials Licensing Branch
US Nuclear Regulatory Commission
Region III
801 Warrenville Road
Lisle, Illinois 60532-4351

Re: Amendment to NRC Material License 34-16710-01
Control # 301564

Dear Mr. Weber:

Enclosed is a letter confirming Dr. Charles Muchnok's successful completion of certification by American Board of Radiology. Also included is an outline of the radiology residency program he completed at West Virginia University.

Hopefully this will provide you with the necessary documentation to add Dr. Muchnok as an authorized user.

Sincerely,



Michael E. Greene
Vice President

MG/cs

Continuation of 301564
FEE EXEMPT

RECEIVED
SEP 17 1996
REGION III

SEP 17 1996

301840

David G. Bragg, M.D.
Robert E. Campbell, M.D.
Edward L. Chaney, M.D.
Gerald D. Dodd, M.D.
Thomas S. Harle, M.D.
Jay R. Harris, M.D.
Robert R. Hattery, M.D.

Robert E. Campbell, M.D., Diagnostic Radiology
Lawrence W. Davis, M.D., Radiation Oncology

5255 E. Williams Circle
Suite 6800
Tucson, Arizona 85711

Phone (520) 790-2900
Fax (520) 790-3200

Andrew K. Poznanski, M.D.
Helen C. Redman, M.D.
Joseph F. Sackett, M.D.
Isaac Sanders, M.D.
Melvyn F. Schreiber, M.D.
Guy H. Simmons, Ph.D.
H. Rodney Withers, M.D.
James E. Youker, M.D.

June 11, 1996

CHARLES MUCHNOK, MD
113 HORIZON DR
MORGANTOWN, WV 26505

40329 / DR / 11 / 11

Dear Doctor Muchnok:

I am pleased to inform you that you passed the oral examination held June 9-12, 1996. The American Board of Radiology grants you its Certificate of Diagnostic Radiology.

The certificate will be sent to the above address in approximately three months. Your name will appear on the certificate as shown above. If you wish your name to appear differently, please notify the Board office within thirty days.

Your name will be included in a Directory published by The American Board of Medical Specialties. It is your responsibility to notify your local and state medical organizations of your certification.

On behalf of the Board of Trustees of The American Board of Radiology, I congratulate you on this achievement.

Sincerely,



M. Paul Capp, M.D.

WEST VIRGINIA UNIVERSITY
DIAGNOSTIC RADIOLOGY RESIDENCY ROTATIONS
JULY 1, 1992 - JUNE 30, 1996

PGY I

July, 1992	Bone
August, 1992	Nuclear Medicine/Mammography
September, 1992	Gastrointestinal/Genitourinary
October, 1992	Ultrasound
November, 1992	CT
December, 1992	Chest (including mammography)
January, 1993	Gastrointestinal/Genitourinary
February, 1993	MRI
March, 1993	Nuclear Medicine
April, 1993	Neuroradiology
May, 1993	Angiography
June, 1993	Chest (including mammography)

PGY II

July, 1993	Gastrointestinal/Genitourinary
August, 1993	MRI
September, 1993	CT
October, 1993	Bone
November, 1993	Ultrasound
December, 1993	Chest
January, 1994	Nuclear Medicine
February, 1994	Angiography
March, 1994	Bone
April, 1994	CT
May, 1994	Neuroradiology
June, 1994	Angiography

PGY III

July, 1994	Chest
August, 1994	CT
September, 1994	Gastrointestinal
October, 1994	Emergency Department/ICU
November, 1994	Ultrasound
December, 1994	VA Hospital
January, 1995	Nuclear Medicine
February, 1995	2 weeks Chest/2 weeks AFIP
March, 1995	AFIP

April, 1995
May, 1995
June, 1995

Angiography
Neuroradiology
Bone

PGY IV

July 3-28, 1995	Pediatric Radiology
July 31-August 26, 1995	MRI
August 28-September 22, 1995	Bone
September 25-October 20, 1995	Mammography
October 23 - November 17, 1995	VA Hospital
November 20-December 15, 1995	Neuroradiology
December 18-January 12, 1996	Angiography
January 15-February 9, 1996	Pediatric Radiology
February 12-March 8, 1996	Nuclear Medicine
March 11-April 5, 1996	Chest
April 8 - May 3, 1995	Ultrasound
May 6-31, 1996	Nuclear Medicine
June 3-28, 1996	CT

SEP 24 1996

Michael E. Greene
Vice President
Bethesda Hospital
2951 Maple Avenue
Zanesville, OH 43701

Dear Mr. Greene:

Enclosed is Amendment No. 16 to your NRC Material License No. 34-16710-01 in accordance with your request.

Please review the enclosed document carefully and be sure that you understand all conditions. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region III office at (630) 829-9887 so that we can provide appropriate corrections and answers.

Please be advised that your license expires at the end of the day, in the month, and year stated in the license. Unless your license has been terminated, you must conduct your program involving byproduct materials in accordance with the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate in accordance with NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers; Inspections," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.
2. Notify NRC, in writing, within 30 days:
 - a. When an authorized user or Radiation Safety Officer permanently discontinues performance of duties under the license or has a name change; or
 - b. When the licensee's mailing address changes (no fee is required if the location of byproduct material remains the same).

301840

3. In accordance with 10 CFR 30.36(b) and/or license condition, notify NRC, promptly, in writing, and request termination of the license when you decide to terminate all activities involving materials authorized under the license.
4. Request and obtain a license amendment before you:
 - a. Receive or use byproduct material for a clinical procedure permitted under Part 35 but not permitted by your license issued pursuant to this Part;
 - b. Permit anyone, except individuals described in 10 CFR 35.13(b), to work as an authorized user under the license;
 - c. Change Radiation Safety Officers;
 - d. Order byproduct material in excess of the amount, or radionuclide, or form different than authorized on the license;
 - e. Add or change the areas of use or address or addresses of use identified in the license application or on the license; or
 - f. Change ownership of your organization.
5. Submit a complete renewal application with proper fee or termination request at least 30 days before the expiration date of your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of byproduct material after your license expires is a violation of NRC regulations. A license will not normally be renewed, except on a case-by-case basis, in instances where licensed material has never been possessed or used.

In addition, please note that NRC Form 313 requires the applicant, by his/her signature, to verify that the applicant understands that all statements contained in the application are true and correct to the best of the applicant's knowledge. The signatory for the application should be the licensee or certifying official rather than a consultant.

You will be periodically inspected by NRC. Failure to conduct your program in accordance with NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC will result in enforcement action against you. This could include issuance of a notice of violation, or imposition of a civil penalty, or an order suspending, modifying or revoking your license as specified in the General Policy and Procedures for NRC Enforcement Actions. Since serious consequences to employees and the public can result from failure to comply with NRC requirements,

M. Greene

-3-

prompt and vigorous enforcement action will be taken when dealing with licensees who do not achieve the necessary meticulous attention to detail and the high standard of compliance which NRC expects of its licensees.

Sincerely,

Original Signed By
Michael F. Weber
Nuclear Materials Licensing Branch

License No.: 34-16710-01

Docket No.: 030-11522

Enclosure: Amendment No. 16

DOCUMENT NAME: M:\03011522.CL6

To receive a copy of this document, indicate in the box: "C" = Copy without attachment/enclosure "E" = Copy with attachment/enclosure "N" = No copy

OFFICE	DNMS/RIII	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
NAME	MWEBER:jaw ^{att}	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
DATE	09/24/96	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

OFFICIAL RECORD COPY



UNITED STATES
NUCLEAR REGULATORY COMMISSION

REGION III
801 WARRENVILLE ROAD
LISLE, ILLINOIS 60532-4351

September 19, 1996

M. A. Graber, M.D.
Radiation Safety Officer
Bethesda Hospital
2951 Maple Avenue
Zanesville, OH 43701

SUBJECT: ACKNOWLEDGEMENT OF CORRESPONDENCE
(Letter Dated 08/30/96)

Dear Licensee:

In response to your request, we have completed the initial processing, which is an administrative review of your application for a(n):

☐ New License ☒ Amendment ☐ Renewal
☐ Termination ☐ Auth User (Amendment not required)
☐ Other _____

No administrative deficiencies were identified during this initial review. However, it should be noted that a technical review may identify omissions in the submitted information.

It appears that your request is routine (see 1-3 below, as applicable).

1. New and amendment actions are normally processed within 90 days, unless we find major deficiencies, or policy issues requiring central program office assistance.
2. Renewal actions are normally processed within 180 days, however, under timely filing (before expiration), you may continue to operate under your existing license.
3. Termination actions are normally processed within 90 days, unless confirmatory surveys following decontamination/decommissioning activities are involved.

A copy of your correspondence has been forwarded to our Licensing Fee and Debt Collection Branch (301/415-6097) for approval of the fee category and amount, if required.

If you have a compelling safety or business-related reason for requesting expedited review, please contact the Materials Licensing Branch at (630) 829-9887. We will try to complete your request as soon as practicable. Any correspondence about this request should reference the control number.

Nuclear Materials Support Branch

Mail Control No. 301840
License No. 34-16710-01